A Biologics License Application, or BLA, is the formal request a company submits to the FDA for permission to sell a biological product in the United States. It’s the biologics equivalent of the New Drug Application (NDA) used for traditional pharmaceuticals, but with stricter manufacturing oversight because biological products are made from living organisms rather than chemical synthesis. The filing fee alone costs over $4.3 million for applications requiring clinical data.
What a BLA Covers
While a standard drug application deals with small molecules made through chemical processes, a BLA covers products derived from biological sources. This includes vaccines, blood and blood products, gene therapies, cellular therapies, and therapeutic proteins like monoclonal antibodies. These products are regulated under the Public Health Service Act, which requires any company manufacturing a biologic for sale across state lines to hold a license for that product.
The distinction matters because biological products are inherently more complex than chemical drugs. A small-molecule drug like ibuprofen has a simple, reproducible chemical structure. A biologic, by contrast, is a large, intricate molecule produced by living cells, meaning even small changes in how it’s manufactured can alter the final product. This is why the BLA process places heavy emphasis on manufacturing details that wouldn’t receive the same scrutiny in a traditional drug application.
What Goes Into a BLA Submission
A BLA is a massive collection of data organized into several major sections. The three pillars are manufacturing information, safety testing in animals, and clinical trial results in humans.
The manufacturing section, formally called Chemistry, Manufacturing, and Controls (CMC), is arguably the most distinctive part of a BLA. It requires detailed information about the biological substance itself, including its description and characterization, method of manufacture, process controls, reference standards, stability data, and container specifications. A separate set of documentation covers the finished product: its composition, packaging methods, test methods, and microbiology. The company must also provide executed batch records for production runs and validated testing methods. Even an environmental assessment is required.
The nonclinical section contains pharmacology, pharmacokinetics, and toxicology studies, typically conducted in animals. These studies establish how the biologic behaves in the body, how it’s processed and eliminated, and what toxic effects it might cause at various doses.
The clinical section contains human trial data organized by each condition the product is intended to treat, along with integrated summaries of how well the product worked. This is the evidence that the biologic is both safe and effective for its proposed uses.
Two Pathways: Original vs. Biosimilar
Not all BLAs follow the same route. The FDA offers two distinct pathways depending on whether the product is new or a near-copy of something already approved.
The 351(a) pathway is for original biological products. This is the full, standalone application that must contain all the data necessary to independently demonstrate safety and effectiveness. It generally includes clinical trials conducted in the relevant patient populations for every treatment indication the manufacturer is seeking. This is the path taken by the first version of any biologic to reach the market.
The 351(k) pathway is an abbreviated route created by the Biologics Price Competition and Innovation Act in 2010. It’s designed for biosimilars, which are products highly similar to an already-approved biologic (called the reference product). Instead of independently proving safety and effectiveness from scratch, a biosimilar manufacturer needs to demonstrate that its product is highly similar in structure and function to the reference product, with only minor differences in clinically inactive components. The biosimilar must use the same mechanism of action, treat the same conditions, and match the reference product’s route of administration, dosage form, and strength. Because the goal is to show similarity rather than build a case from the ground up, biosimilar manufacturers generally don’t need to conduct as many expensive and lengthy clinical trials.
Review Timelines and Fees
Once a BLA is submitted, the FDA has 60 days to decide whether to formally accept it for review (called “filing”). From that filing date, the clock starts. For standard applications, the FDA’s goal is to review and act on 90% of original BLAs within 10 months. Products that qualify for priority review, typically those offering significant improvements over existing treatments, get a faster target of 6 months.
The cost of filing is substantial. For fiscal year 2025, the application fee for a BLA requiring clinical data is $4,310,002. These fees, collected under the Prescription Drug User Fee Act (PDUFA), fund the FDA’s review operations. The high price tag reflects the complexity and resource intensity of evaluating biological products.
Manufacturing Facility Inspections
One feature that sets the BLA process apart is the pre-approval inspection, or PAI. Before approving a biologic, the FDA typically sends inspectors to the manufacturing facility to confirm that real-world operations match what the company described in its application.
The FDA decides whether a PAI is needed by assessing the product’s risk profile, the complexity of the manufacturing process, and the accuracy of the quality data submitted. A PAI can be triggered whenever there’s a need to verify that critical quality information is reliable. The agency aims to provide manufacturers at least 60 days’ notice before an inspection, but reserves the right to inspect at any point during the review cycle. If the FDA already has sufficient information about a facility, it may skip the inspection entirely, though this is less common for novel biologics.
What Happens After Approval
Approval doesn’t end a company’s obligations. The FDA can impose two types of ongoing requirements on approved biologics.
Postmarketing requirements (PMRs) are studies or clinical trials that companies are legally required to conduct. These can include trials to confirm clinical benefit for products approved under accelerated pathways, pediatric studies deferred from the original application, and studies to assess known or suspected serious risks. PMRs aren’t optional: they’re mandated by statute or regulation.
Postmarketing commitments (PMCs) are studies that a company has agreed to conduct but aren’t legally required. These tend to be less urgent investigations that can fill remaining gaps in knowledge about a product’s long-term performance.
In calendar year 2024, the Center for Biologics Evaluation and Research (CBER) approved 17 biologics license applications along with 26 BLA supplements, which are changes or additions to already-approved products. That number reflects only the biologics reviewed by CBER; some biologics, particularly therapeutic proteins, are reviewed by the FDA’s drug center instead.